Other studies have shown that transforming growth factor beta receptor (TGF-βR) ablation using genome-editing tools raised prostate-specific membrane antigen (PSMA)-specific CAR T cell expansion and powerfully motivated PSMA-expressing prostate cancer eradication in vitro. This evidence concerns the gene FOLH1 and prostate cancer.